CAB

DRUG4 trials

Sponsors

ViiV Healthcare, Changhai Hospital, Radboud Universitair Medisch Centrum

Conditions

HIVHIV InfectionsInfection, Human Immunodeficiency VirusPancreatic Diseases

Phase 1

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

CompletedNCT02411435

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2015-07-31End: 2015-09-30Updated: 2016-01-06

Phase 2

A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)

Not yet recruitingNCT07816250

ViiV HealthcareHIV Infections

Start: 2026-10-19End: 2032-06-11Target: 200Updated: 2026-09-11

Unknown Phase

Relative bioavailability study to investigate a potential interaction between dolutegravir (DTG) and tenofovir alafenamide fumarate/emtricitabine (F/TAF) administered as paediatric tablet formulations.

Active, not recruitingNL-OMON51616

Radboud Universitair Medisch CentrumHIV

Start: 2022-11-02Target: 16Updated: 2026-08-03

The 22G Franseen Needle Combined With Different Aspiration Techniques for Endoscopic Ultrasound-guided Fine-needle Biopsy

Not yet recruitingNCT07023549

Changhai HospitalPancreatic Diseases

Start: 2025-07-01End: 2027-05-31Target: 270Updated: 2025-06-17

Related Papers

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy2017-07-2547 citations